<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD09260000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P09382</UniProt_ID>
  <Seq_Length>135</Seq_Length>
  <Molecule_Weight>14716</Molecule_Weight>
  <KEGG_ID>hsa:3956</KEGG_ID>
  <Orthology_ID>K06830</Orthology_ID>
  <Function_Summary>May regulate apoptosis, cell proliferation and cell differentiation. Binds beta-galactoside and a wide array of complex carbohydrates. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase.</Function_Summary>
  <Pfam_ID>PF00337:Gal-bind_lectin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>2</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>HBL</Alias>
      <Alias>14 kDa laminin-binding protein</Alias>
      <Alias>HPL</Alias>
      <Alias>S-Lac lectin 1</Alias>
      <Alias>Lectin galactoside-binding soluble 1</Alias>
      <Alias>HLBP14</Alias>
      <Alias>Putative MAPK-activating protein PM12</Alias>
      <Alias>Lactose-binding lectin 1</Alias>
      <Alias>14 kDa lectin</Alias>
      <Alias>Beta-galactoside-binding lectin L-14-I</Alias>
      <Alias>Gal-1</Alias>
      <Alias>Galaptin</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any glycoside in which the sugar group is galactose.</Detail>
      <Keyword>Galactoside binding</Keyword>
      <Ontology_ID>GO:0016936</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Conveys a signal across a cell to trigger a change in cell function or state. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.</Detail>
      <Keyword>Signal transducer activity</Keyword>
      <Ontology_ID>GO:0004871</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any mono-, di- or trisaccharide carbohydrate.</Detail>
      <Keyword>Sugar binding</Keyword>
      <Ontology_ID>GO:0005529</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the occurrence or rate of cell death by apoptosis.</Detail>
      <Keyword>Regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0042981</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of an I-kappaB kinase/NF-kappaB induced cascade.</Detail>
      <Keyword>Positive regulation of I-kappaB kinase/NF-kappaB cascade</Keyword>
      <Ontology_ID>GO:0043123</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>2</Position>
      <PTM_Type>N-acetylalanine</PTM_Type>
    </PTM>
    <PTM>
      <Position>29</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>105</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MACGLVASNLNLKPGECLRVRGEVAPDAKSFVLNLGKDSNNLCLHFNPRFNAHGDANTIVCNSKDGGAWGTEQREAVFPFQPGSVAEVCITFDQANLTVKLPDGYEFKFPNRLNLEAINYMAADGDFKIKCVAFD</Protein_Seq>
    <DNA_Seq>AGTTAAAAGGGTGGGAGCGTCCGGGGGCCCATCTCTCTCGGGTGGAGTCTTCTGACAGCTGGTGCGCCTGCCCGGGAACATCCTCCTGGACTCAATCATGGCTTGTGGTCTGGTCGCCAGCAACCTGAATCTCAAACCTGGAGAGTGCCTTCGAGTGCGAGGCGAGGTGGCTCCTGACGCTAAGAGCTTCGTGCTGAACCTGGGCAAAGACAGCAACAACCTGTGCCTGCACTTCAACCCTCGCTTCAACGCCCACGGCGACGCCAACACCATCGTGTGCAACAGCAAGGACGGCGGGGCCTGGGGGACCGAGCAGCGGGAGGCTGTCTTTCCCTTCCAGCCTGGAAGTGTTGCAGAGGTGTGCATCACCTTCGACCAGGCCAACCTGACCGTCAAGCTGCCAGATGGATACGAATTCAAGTTCCCCAACCGCCTCAACCTGGAGGCCATCAACTACATGGCAGCTGACGGTGACTTCAAGATCAAATGTGTGGCCTTTGACTGAAATCAGCCAGCCCATGGCCCCCAATAAAGGCAGCTGCCTCTGCTCCCTCTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Cardiac</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Placenta</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Hematopoietic cells</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Fetal membranes</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Neurons</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Thymus</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Maternal decidua</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Smooth</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Proteinaceous extracellular matrix</CellLocal>
      <Ontology_ID>GO:0005578</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>LGALS1</Gene_Name>
    <Gene_ID>3956</Gene_ID>
    <Genbank_ACCN>NM_002305</Genbank_ACCN>
    <Protein_ACCN>NP_002296</Protein_ACCN>
    <HGNC_ID>6561</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3956</Gene_URL>
    <UCSC_ID>uc003atn.3</UCSC_ID>
    <EMBL_ID>ENSG00000100097</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Fucosidosis</Disease_Name>
      <Disease_Detail>Fucosidosis</Disease_Detail>
      <Disease_DB>FCS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fucosidosis?search=LGALS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Benign Metastasizing Leiomyoma</Disease_Name>
      <Disease_Detail>Benign Metastasizing Leiomyoma</Disease_Detail>
      <Disease_DB>BNG041</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/benign_metastasizing_leiomyoma?search=LGALS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteosarcoma</Disease_Name>
      <Disease_Detail>Osteosarcoma</Disease_Detail>
      <Disease_DB>OST018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteosarcoma?search=LGALS1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chondroblastic Osteosarcoma</Disease_Name>
      <Disease_Detail>Chondroblastic Osteosarcoma</Disease_Detail>
      <Disease_DB>CHN003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chondroblastic_osteosarcoma?search=LGALS1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Galectin-1 dimer</PDB_Title>
      <PDB_ID>2KM2</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KM2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity.</PubMed_Title>
      <Author>Nesmelova, I.V., et al.</Author>
      <Journal>J.Mol.Biol.(2010)397:1209-1230</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20184898?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1</PDB_Title>
      <PDB_ID>1W6N</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W6N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH GALACTOSE</PDB_Title>
      <PDB_ID>1W6M</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W6M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding.</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF HUMAN GALECTIN-1</PDB_Title>
      <PDB_ID>1GZW</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GZW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human galectin-1 in complex with methyl 2-O-acetyl-3-O-toluoyl-beta-D-talopyranoside</PDB_Title>
      <PDB_ID>3T2T</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3T2T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Taloside inhibitors of Galectin-1 and Galectin-3</PubMed_Title>
      <Author>Collins PM, et al.</Author>
      <Journal>Chem Biol Drug Des. 2012,79(3):339-346.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22136701?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH N-ACETYL-LACTOSAMINE</PDB_Title>
      <PDB_ID>1W6P</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W6P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF C2S HUMAN GALECTIN-1 COMPLEXED WITH LACTOSE</PDB_Title>
      <PDB_ID>1W6O</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W6O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957-970</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of mutant galectin-1/lactose complex</PDB_Title>
      <PDB_ID>2ZKN</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZKN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Functional and structural bases of a cysteine-less mutant as a long-lasting substitute for galectin-1</PubMed_Title>
      <Author>Nishi, N., et al.</Author>
      <Journal>Glycobiology(2008)18:1065-1073</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18796645?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human galectin-1 in complex with thiodigalactoside</PDB_Title>
      <PDB_ID>3OYW</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OYW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model</PubMed_Title>
      <Author>Stannard KA, et al.</Author>
      <Journal>Cancer Lett. 2010,299(2):95-110.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20826047?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-RAY CRYSTAL STRUCTURE OF R111H HUMAN GALECTIN-1</PDB_Title>
      <PDB_ID>1W6Q</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1W6Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Growth-Regulatory Human Galectin-1: Crystallographic Characterisation of the Structural Changes Induced by Single-Site Mutations and Their Impact on the Thermodynamics of Ligand Binding</PubMed_Title>
      <Author>Lopez-Lucendo, M.I.F., et al.</Author>
      <Journal>J.Mol.Biol.(2004)343:957</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15476813?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human galectin-1 in complex with lactobionic acid</PDB_Title>
      <PDB_ID>3OY8</PDB_ID>
      <Resolution>2.19</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OY8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model</PubMed_Title>
      <Author>Stannard KA, et al.</Author>
      <Journal>Cancer Lett. 2010,299(2):95-110.</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20826047?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.fb.b.e.c.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1gzw</CATH_URL>
  </Fold>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD09260001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09260002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>